Functions of myc:max in the control of cell proliferation and tumorigenesis.

[1]  S. Mai,et al.  Genomic instability in MycER-activated Rat1A-MycER cells , 1996, Chromosome Research.

[2]  R. Eisenman,et al.  Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome. , 2004, Human molecular genetics.

[3]  S. Cawley,et al.  Unbiased Mapping of Transcription Factor Binding Sites along Human Chromosomes 21 and 22 Points to Widespread Regulation of Noncoding RNAs , 2004, Cell.

[4]  J. Cleveland,et al.  Mnt Loss Triggers Myc Transcription Targets, Proliferation, Apoptosis, and Transformation , 2004, Molecular and Cellular Biology.

[5]  A. Wynshaw-Boris,et al.  Evidence of Mnt-Myc Antagonism Revealed by Mnt Gene Deletion , 2004, Cell cycle.

[6]  D. Felsher.  Oncogenes as therapeutic targets. , 2004, Seminars in cancer biology.

[7]  F. Conlon,et al.  T‐box genes in early embryogenesis , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.

[8]  John L Cleveland,et al.  Myc pathways provoking cell suicide and cancer , 2003, Oncogene.

[9]  A. Ruddell,et al.  B lymphocyte-specific c-Myc expression stimulates early and functional expansion of the vasculature and lymphatics during lymphomagenesis. , 2003, The American journal of pathology.

[10]  A. Kraft,et al.  The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death* , 2003, Journal of Biological Chemistry.

[11]  T. Möröy,et al.  Miz1 Is Required for Early Embryonic Development during Gastrulation , 2003, Molecular and Cellular Biology.

[12]  J. Cleveland,et al.  c-Myc Augments Gamma Irradiation-Induced Apoptosis by Suppressing Bcl-XL , 2003, Molecular and Cellular Biology.

[13]  A. Wynshaw-Boris,et al.  Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis , 2003, The EMBO journal.

[14]  Elisa de Stanchina,et al.  Tumor promotion by Mdm2 splice variants unable to bind p53. , 2003, Cancer research.

[15]  Takashi Okamoto,et al.  c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis , 2003, Oncogene.

[16]  D. Felsher,et al.  Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Esparza-Gómez,et al.  The spectrum of plasma cell neoplasia in oral pathology. , 2003, Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal.

[18]  L. Chodosh,et al.  The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. , 2003, Genes & development.

[19]  Ruedi Aebersold,et al.  Quantitative proteomic analysis of chromatin-associated factors , 2003, Journal of the American Society for Mass Spectrometry.

[20]  D. Livingston,et al.  MYC recruits the TIP60 histone acetyltransferase complex to chromatin , 2003, EMBO reports.

[21]  Peggy J. Farnham,et al.  Analysis of Myc Bound Loci Identified by CpG Island Arrays Shows that Max Is Essential for Myc-Dependent Repression , 2003, Current Biology.

[22]  B. Lüscher,et al.  Stimulation of c‐MYC transcriptional activity and acetylation by recruitment of the cofactor CBP , 2003, EMBO reports.

[23]  S. Kim,et al.  Skp2 regulates Myc protein stability and activity. , 2003, Molecular cell.

[24]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[25]  K. Nakayama,et al.  The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. , 2003, Molecular cell.

[26]  B. Edgar,et al.  Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. , 2003, Genes & development.

[27]  M. Roussel,et al.  Myc-mediated proliferation and lymphomagenesis, but not apoptosis, are compromised by E2f1 loss. , 2003, Molecular cell.

[28]  M. Cole,et al.  The Mad and Myc Basic Domains Are Functionally Equivalent* , 2003, The Journal of Biological Chemistry.

[29]  T. Greiner,et al.  Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis , 2003, The EMBO journal.

[30]  R. Weinberg,et al.  Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. , 2003, Cancer cell.

[31]  M. Eilers,et al.  Transcriptional repression by Myc. , 2003, Trends in cell biology.

[32]  S. Lowe,et al.  Tumor suppression by Ink4a-Arf: progress and puzzles. , 2003, Current opinion in genetics & development.

[33]  Stephen K. Burley,et al.  X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA Molecular Bases of Regulation by Proto-Oncogenic Transcription Factors , 2003, Cell.

[34]  M. Eilers,et al.  Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter , 2003, Oncogene.

[35]  R. Eisenman,et al.  Direct activation of RNA polymerase III transcription by c-Myc , 2003, Nature.

[36]  Tapio Visakorpi,et al.  Molecular genetics of prostate cancer , 2001, Urology.

[37]  M. Moynahan,et al.  The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans , 2002, Oncogene.

[38]  P. Farnham,et al.  Myc Recruits P-TEFb to Mediate the Final Step in the Transcriptional Activation of the cad Promoter* , 2002, The Journal of Biological Chemistry.

[39]  Hans Clevers,et al.  The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells , 2002, Cell.

[40]  J. Massagué,et al.  Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage , 2002, Nature.

[41]  R. Eisenman,et al.  N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. , 2002, Genes & development.

[42]  B. Edgar,et al.  Why size matters: altering cell size. , 2002, Current opinion in genetics & development.

[43]  Ruedi Aebersold,et al.  Quantitative proteomic analysis of Myc oncoprotein function , 2002, The EMBO journal.

[44]  John L Cleveland,et al.  c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. , 2002, Genes & development.

[45]  Stella Pelengaris,et al.  c-MYC: more than just a matter of life and death , 2002, Nature Reviews Cancer.

[46]  Carla Grandori,et al.  Modulation of T‐lymphocyte development, growth and cell size by the Myc antagonist and transcriptional repressor Mad1 , 2002, The EMBO journal.

[47]  M. Eilers,et al.  Negative regulation of the mammalian UV response by Myc through association with Miz-1. , 2002, Molecular cell.

[48]  R. Eisenman,et al.  Myc and Mad bHLHZ domains possess identical DNA-binding specificities but only partially overlapping functions in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  M. van Lohuizen,et al.  The T-box Repressors TBX2 and TBX3Specifically Regulate the Tumor Suppressor Genep14 ARF via a Variant T-site in the Initiator* , 2002, The Journal of Biological Chemistry.

[50]  M. Cole,et al.  TRRAP-Dependent and TRRAP-Independent Transcriptional Activation by Myc Family Oncoproteins , 2002, Molecular and Cellular Biology.

[51]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[52]  G. Evan,et al.  Myc-Is this the oncogene from Hell? , 2002, Cancer cell.

[53]  P. Hurlin,et al.  Tbx3 impinges on the p53 pathway to suppress apoptosis, facilitate cell transformation and block myogenic differentiation , 2002, Oncogene.

[54]  David M. Livingston,et al.  A Complex with Chromatin Modifiers That Occupies E2F- and Myc-Responsive Genes in G0 Cells , 2002, Science.

[55]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[56]  Thierry Fest,et al.  c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis , 2002, Oncogene.

[57]  C. Albanese,et al.  E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. , 2002, Molecular cell.

[58]  James M. Roberts,et al.  MAD1 and p27KIP1 Cooperate To Promote Terminal Differentiation of Granulocytes and To Inhibit Myc Expression and Cyclin E-CDK2 Activity , 2002, Molecular and Cellular Biology.

[59]  G. Wahl,et al.  c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. , 2002, Molecular cell.

[60]  A. Menssen,et al.  Characterization of the c-MYC-regulated transcriptome by SAGE: Identification and analysis of c-MYC target genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[61]  John T. Powers,et al.  ARF Differentially Modulates Apoptosis Induced by E2F1 and Myc , 2002, Molecular and Cellular Biology.

[62]  M. MacDonald,et al.  TBX-3, the Gene Mutated in Ulnar-Mammary Syndrome, Is a Negative Regulator of p19 ARF and Inhibits Senescence* , 2002, The Journal of Biological Chemistry.

[63]  R. Kingston,et al.  Cooperation between Complexes that Regulate Chromatin Structure and Transcription , 2002, Cell.

[64]  M. Henriksson,et al.  Repression of in vivo growth of Myc/Ras transformed tumor cells by Mad1 , 2002, Oncogene.

[65]  Jeffrey M. Trimarchi,et al.  Transcription: Sibling rivalry in the E2F family , 2002, Nature Reviews Molecular Cell Biology.

[66]  Mark J. Murphy,et al.  c-Myc regulates mammalian body size by controlling cell number but not cell size , 2001, Nature.

[67]  D. Eick,et al.  Myc/Max/Mad regulate the frequency but not the duration of productive cell cycles , 2001, EMBO reports.

[68]  Bax Loss Impairs Myc-Induced Apoptosis and Circumvents the Selection of p53 Mutations during Myc-Mediated Lymphomagenesis , 2001, Molecular and Cellular Biology.

[69]  F. Zindy,et al.  Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. , 2001, Genes & development.

[70]  P. Hurlin,et al.  The interplay between Mad and Myc in proliferation and differentiation. , 2001, Trends in cell biology.

[71]  B. Lüscher,et al.  Function and regulation of the transcription factors of the Myc/Max/Mad network. , 2001, Gene.

[72]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[73]  M. Eilers,et al.  Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. , 2001, Genes & development.

[74]  P. Fernandez,et al.  Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. , 2001, Genes & development.

[75]  M. Roussel,et al.  Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 Is Bypassed during Lymphomagenesis , 2001, Molecular and Cellular Biology.

[76]  S. Kunjibettu,et al.  The ATM-related domain of TRRAP is required for histone acetyltransferase recruitment and Myc-dependent oncogenesis. , 2001, Genes & development.

[77]  M E Greenberg,et al.  Myc requires distinct E2F activities to induce S phase and apoptosis. , 2001, Molecular cell.

[78]  A. Hayday,et al.  Defining the specific physiological requirements for c-Myc in T cell development , 2001, Nature Immunology.

[79]  J. Massagué,et al.  TGFβ influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b , 2001, Nature Cell Biology.

[80]  J. Massagué,et al.  Repression of p15INK4b expression by Myc through association with Miz-1 , 2001, Nature Cell Biology.

[81]  D. W. Kim,et al.  Repression of transcription of the p27Kip1 cyclin-dependent kinase inhibitor gene by c-Myc , 2001, Oncogene.

[82]  Nikita Popov,et al.  Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[83]  B. Amati,et al.  Function of the c-Myc oncoprotein in chromatin remodeling and transcription. , 2001, Biochimica et biophysica acta.

[84]  A Ballabio,et al.  WBSCR14, a gene mapping to the Williams--Beuren syndrome deleted region, is a new member of the Mlx transcription factor network. , 2001, Human molecular genetics.

[85]  G. Evan,et al.  Expression of Mad1 in T cells leads to reduced thymic cellularity and impaired mitogen-induced proliferation , 2001, Oncogene.

[86]  R. Cardiff,et al.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.

[87]  R. Eisenman,et al.  Targeted Deletion of the S-Phase-Specific Myc Antagonist Mad3 Sensitizes Neuronal and Lymphoid Cells to Radiation-Induced Apoptosis , 2001, Molecular and Cellular Biology.

[88]  U. Weidle,et al.  The transcriptional program of a human B cell line in response to Myc. , 2001, Nucleic acids research.

[89]  F. Alt,et al.  Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. , 2001, Immunity.

[90]  John N. Hutchinson,et al.  Transgenic mouse models of human breast cancer , 2000, Oncogene.

[91]  W. Hahn,et al.  Genes involved in senescence and immortalization. , 2000, Current opinion in cell biology.

[92]  E. Deitch,et al.  G-protein receptor responses in trauma neutrophils. , 2000, The Journal of trauma.

[93]  D. Ayer,et al.  MondoA, a Novel Basic Helix-Loop-Helix–Leucine Zipper Transcriptional Activator That Constitutes a Positive Branch of a Max-Like Network , 2000, Molecular and Cellular Biology.

[94]  W. Ansorge,et al.  Induction of cyclin E–cdk2 kinase activity, E2F‐dependent transcription and cell growth by Myc are genetically separable events , 2000, The EMBO journal.

[95]  Marc J. van de Vijver,et al.  Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19ARF) and is amplified in a subset of human breast cancers , 2000, Nature Genetics.

[96]  A. Iavarone,et al.  Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins , 2000, Nature.

[97]  M. Cole,et al.  Complementation of Myc-dependent cell proliferation by cDNA expression library screening , 2000, Oncogene.

[98]  Y Taya,et al.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. , 2000, Genes & development.

[99]  S. R. Hann,et al.  A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[100]  T. Fotsis,et al.  The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. , 2000, Cancer research.

[101]  M. Roussel,et al.  Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. , 2000, Genes & development.

[102]  G. Daley,et al.  A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts , 2000, Oncogene.

[103]  A. Reymond,et al.  Mlx, a new Max-like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway? , 2000, Oncogene.

[104]  R. Eisenman,et al.  Analysis of Myc/Max/Mad network members in adipogenesis: Inhibition of the proliferative burst and differentiation by ectopically expressed Mad1 , 2000, Journal of cellular physiology.

[105]  F. Alt,et al.  N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. , 2000, Genes & development.

[106]  P. Neiman,et al.  Angiogenesis is an early event in the generation of myc-induced lymphomas , 2000, Oncogene.

[107]  N. Mailand,et al.  Involvement of Myc Activity in a G1/S-Promoting Mechanism Parallel to the pRb/E2F Pathway , 2000, Molecular and Cellular Biology.

[108]  O. Volpert,et al.  An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[109]  E. Lander,et al.  Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[110]  J F Barrett,et al.  Identification of CDK4 as a target of c-MYC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[111]  T. Littlewood,et al.  Action of Myc in vivo - proliferation and apoptosis. , 2000, Current opinion in genetics & development.

[112]  M. Cole,et al.  An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. , 2000, Molecular cell.

[113]  Ken Chen,et al.  Gene-target recognition among members of the Myc superfamily and implications for oncogenesis , 2000, Nature Genetics.

[114]  B. Amati,et al.  Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis. , 2000, Nucleic acids research.

[115]  M. Cole,et al.  The Essential Cofactor TRRAP Recruits the Histone Acetyltransferase hGCN5 to c-Myc , 2000, Molecular and Cellular Biology.

[116]  E. Mekada,et al.  Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras , 2000, Oncogene.

[117]  R. DePinho,et al.  Essential role for Max in early embryonic growth and development. , 2000, Genes & development.

[118]  R. Eisenman,et al.  The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.

[119]  Gustavo Droguett,et al.  DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation , 2000, Nature Cell Biology.

[120]  D. Ayer,et al.  Mlx, a Novel Max-like BHLHZip Protein That Interacts with the Max Network of Transcription Factors* , 1999, The Journal of Biological Chemistry.

[121]  N. Jenkins,et al.  Mga, a dual‐specificity transcription factor that interacts with Max and contains a T‐domain DNA‐binding motif , 1999, The EMBO journal.

[122]  R. Eisenman,et al.  Dwarfism and dysregulated proliferation in mice overexpressing the MYC antagonist MAD1. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[123]  R. Eisenman,et al.  c-Myc enhances protein synthesis and cell size during B lymphocyte development. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[124]  U. Weidle,et al.  Control of cell growth by c-Myc in the absence of cell division , 1999, Current Biology.

[125]  S. Lowe,et al.  INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.

[126]  M. Roussel,et al.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.

[127]  W. Ansorge,et al.  Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27 , 1999, The EMBO journal.

[128]  A. Sewing,et al.  Cyclins D1 and D2 mediate Myc‐induced proliferation via sequestration of p27Kip1 and p21Cip1 , 1999, The EMBO journal.

[129]  D. Prober,et al.  Drosophila myc Regulates Cellular Growth during Development , 1999, Cell.

[130]  J. Tonn,et al.  Analysis of the max‐binding protein MNT in human medulloblastomas , 1999, International journal of cancer.

[131]  L. Kedes,et al.  Twist is a potential oncogene that inhibits apoptosis. , 1999, Genes & development.

[132]  M. Schwab,et al.  Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells. , 1999, European journal of biochemistry.

[133]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[134]  A. Kraft,et al.  The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway , 1999, Oncogene.

[135]  John M. Sedivy,et al.  c-Myc Regulates Cyclin D-Cdk4 and -Cdk6 Activity but Affects Cell Cycle Progression at Multiple Independent Points , 1999, Molecular and Cellular Biology.

[136]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[137]  M. Cole,et al.  The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation , 1999, Oncogene.

[138]  G. Evan,et al.  Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. , 1999, Molecular cell.

[139]  S. G. Cheng,et al.  c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function , 1999, Nature Genetics.

[140]  M. Roussel,et al.  Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[141]  L. Chin,et al.  Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation , 1999, Oncogene.

[142]  J. Nevins,et al.  Ras enhances Myc protein stability. , 1999, Molecular cell.

[143]  R. Dalla‐Favera,et al.  Direct activation of TERT transcription by c-MYC , 1999, Nature Genetics.

[144]  K Kornfeld,et al.  Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. , 1999, Genes & development.

[145]  M. Cole,et al.  The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.

[146]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[147]  R. DePinho,et al.  Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth , 1998, Nature.

[148]  D. Ledbetter,et al.  The human ROX gene: genomic structure and mutation analysis in human breast tumors. , 1998, Genomics.

[149]  A. M. Morrison,et al.  Identification of BSAP (Pax‐5) target genes in early B‐cell development by loss‐ and gain‐of‐function experiments , 1998, The EMBO journal.

[150]  H. Konishi,et al.  Molecular Analysis of a Myc Antagonist, ROX/Mnt, at 17p13.3 in Human Lung Cancers , 1998, Japanese journal of cancer research : Gann.

[151]  E. Kremmer,et al.  Identification and Characterization of Specific DNA-binding Complexes Containing Members of the Myc/Max/Mad Network of Transcriptional Regulators* , 1998, The Journal of Biological Chemistry.

[152]  R. Eisenman,et al.  Sequential expression of the MAD family of transcriptional repressors during differentiation and development , 1998, Oncogene.

[153]  R. Eisenman,et al.  Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation , 1998, The EMBO journal.

[154]  C. Y. Wang,et al.  Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. , 1997, Science.

[155]  W. Ansorge,et al.  Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes , 1997, Oncogene.

[156]  L. Hennighausen,et al.  Cre-mediated gene deletion in the mammary gland. , 1997, Nucleic acids research.

[157]  J. Sedivy,et al.  Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[158]  R. Bernards,et al.  Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity , 1997, Oncogene.

[159]  J. Nevins,et al.  Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals , 1997, Molecular and cellular biology.

[160]  R A Jungmann,et al.  c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[161]  E. Kremmer,et al.  Cell growth inhibition by the Mad/Max complex through recruitment of histone deacetylase activity , 1997, Current Biology.

[162]  Joseph R. Nevins,et al.  Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F , 1997, Nature.

[163]  Andreas Sewing,et al.  Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27Kip1 binding to newly formed complexes , 1997, Oncogene.

[164]  D. Ledbetter,et al.  Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non‐canonical E box and acts as a transcriptional repressor , 1997, The EMBO journal.

[165]  Wen‐Ming Yang,et al.  Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression , 1997, Cell.

[166]  Stuart L Schreiber,et al.  Histone Deacetylase Activity Is Required for Full Transcriptional Repression by mSin3A , 1997, Cell.

[167]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[168]  R. Eisenman,et al.  Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. , 1997, Genes & development.

[169]  R. Eisenman,et al.  Mnt: a novel Max-interacting protein and Myc antagonist. , 1997, Current topics in microbiology and immunology.

[170]  M. Linial,et al.  Viral Myc Oncoproteins in Infected Fibroblasts Down-modulate Thrombospondin-1, a Possible Tumor Suppressor Gene* , 1996, The Journal of Biological Chemistry.

[171]  An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. , 1996, Molecular and cellular biology.

[172]  D. Beach,et al.  Cdc25 cell-cycle phosphatase as a target of c-myc , 1996, Nature.

[173]  M. Roussel,et al.  Inhibition of cell proliferation by the Mad1 transcriptional repressor , 1996, Molecular and cellular biology.

[174]  W. Ansorge,et al.  Activation of cyclin‐dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. , 1996, The EMBO journal.

[175]  R. DePinho,et al.  Expression and activity of L-Myc in normal mouse development , 1996, Molecular and cellular biology.

[176]  D. Hanahan,et al.  Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. , 1995, Oncogene.

[177]  M. Pagano,et al.  Identification of a Myc‐dependent step during the formation of active G1 cyclin‐cdk complexes. , 1995, The EMBO journal.

[178]  C. Seelos,et al.  Differential effects by Mad and Max on transformation by cellular and viral oncoproteins. , 1995, Oncogene.

[179]  G. Evan,et al.  A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. , 1995, Nucleic acids research.

[180]  R. Eisenman,et al.  Mad-max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3 , 1995, Cell.

[181]  L. Chin,et al.  An amino-terminal domain of Mxi1 mediates anti-myc oncogenic activity and interacts with a homolog of the Yeast Transcriptional Repressor SIN3 , 1995, Cell.

[182]  R. Eisenman,et al.  Overexpressed max is not oncogenic and attenuates myc-induced lymphoproliferation and lymphomagenesis in transgenic mice. , 1995, Oncogene.

[183]  N. Hay,et al.  Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. , 1994, Genes & development.

[184]  H. Hermeking,et al.  Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.

[185]  G. Prendergast,et al.  c‐Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. , 1994, The EMBO journal.

[186]  R. DePinho,et al.  Suppression of Myc, but not E1a, transformation activity by Max-associated proteins, Mad and Mxi1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[187]  G. Evan,et al.  The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max. , 1993, The EMBO journal.

[188]  G. Casey,et al.  Functional evidence for a breast cancer growth suppressor gene on chromosome 17. , 1993, Human molecular genetics.

[189]  G. Merlo,et al.  A Locus on Chromosome 17P13.3, Associated with a High S‐Phase Index Is Distinct from the p53 Gene in Breast Cancer a , 1993, Annals of the New York Academy of Sciences.

[190]  R. Eisenman,et al.  A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. , 1993, Genes & development.

[191]  J. Rossant,et al.  Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus. , 1993, Development.

[192]  D. Gillespie,et al.  Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity. , 1993, Oncogene.

[193]  Stephen K. Burley,et al.  Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain , 1993, Nature.

[194]  A. Bradley,et al.  A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. , 1993, Genes & development.

[195]  H. Kondoh,et al.  Defects of embryonic organogenesis resulting from targeted disruption of the N-myc gene in the mouse. , 1993, Development.

[196]  R. Brent,et al.  Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites , 1993, Cell.

[197]  Bruno Amati,et al.  Oncogenic activity of the c-Myc protein requires dimerization with Max , 1993, Cell.

[198]  R. Eisenman,et al.  Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity , 1993, Cell.

[199]  N. Hay,et al.  Sequence-specific transcriptional activation by Myc and repression by Max , 1993, Molecular and cellular biology.

[200]  V. Stewart,et al.  Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. , 1992, Genes & development.

[201]  A. Perkins,et al.  Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. , 1992, Genes & development.

[202]  G. Evan,et al.  Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.

[203]  R. Eisenman,et al.  Myc and Max proteins possess distinct transcriptional activities , 1992, Nature.

[204]  G. Evan,et al.  Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max , 1992, Nature.

[205]  K. Alitalo,et al.  Amplification and rearrangement of L-myc in human small-cell lung cancer. , 1992, Mutation research.

[206]  K. Alitalo,et al.  Alternative Forms of Max as Enhancers or Suppressors of Myc-Ras Cotransformation , 1992, Science.

[207]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[208]  M. Cole,et al.  Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/Max heterodimers. , 1992, Genes & development.

[209]  R. Eisenman,et al.  Myc and Max associate in vivo. , 1992, Genes & development.

[210]  A. Patel,et al.  myc function and regulation. , 1992, Annual review of biochemistry.

[211]  C. Dang,et al.  Max: functional domains and interaction with c-Myc. , 1992, Genes & development.

[212]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[213]  A. Berns.  Tumorigenesis in transgenic mice: Identification and characterization of synergizing oncogenes , 1991, Journal of cellular biochemistry.

[214]  G. Prendergast,et al.  Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation , 1991, Cell.

[215]  H. Kondoh,et al.  Embryonic lethality resulting from disruption of both N-myc alleles in mouse zygotes. , 1991, The New biologist.

[216]  J. Bishop,et al.  The MYC protein activates transcription of the alpha‐prothymosin gene. , 1991, The EMBO journal.

[217]  K. Alitalo,et al.  Expression of the myc proto-oncogenes in developing human fetal brain. , 1990, Oncogene.

[218]  R. Eisenman,et al.  New light on Myc and Myb. Part II. Myb. , 1990, Genes & development.

[219]  H. Weintraub,et al.  Sequence-specific DNA binding by the c-Myc protein. , 1990, Science.

[220]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[221]  J. Barrett,et al.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription , 1990, Molecular and cellular biology.

[222]  E. Prochownik,et al.  The leucine zipper of c-Myc is required for full inhibition of erythroleukemia differentiation , 1990, Molecular and cellular biology.

[223]  C. Dang,et al.  Definition of the activities and properties of c-myc required to inhibit cell differentiation. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[224]  D. Gillespie,et al.  The leucine zipper domain of avian cMyc is required for transformation and autoregulation. , 1990, Oncogene.

[225]  R. Stein,et al.  Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[226]  Didier Picard,et al.  Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells , 1989, Nature.

[227]  J. Bishop,et al.  Contrasting patterns of myc and N-myc expression during gastrulation of the mouse embryo. , 1989, Genes & development.

[228]  David Baltimore,et al.  A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins , 1989, Cell.

[229]  C. Dang,et al.  Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein , 1989, Nature.

[230]  F. Alt,et al.  N-myc proto-oncogene expression during organogenesis in the developing mouse as revealed by in situ hybridization , 1988, The Journal of cell biology.

[231]  S. Freytag.  Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1 , 1988, Molecular and cellular biology.

[232]  M. Goldfarb,et al.  Growth factor-deprived BALB/c 3T3 murine fibroblasts can enter the S phase after induction of c-myc gene expression , 1987, Molecular and cellular biology.

[233]  P. Leder,et al.  Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo , 1987, Cell.

[234]  K. Maruyama,et al.  myc and E1A oncogenes alter the responses of PC12 cells to nerve growth factor and block differentiation. , 1987, Oncogene.

[235]  V. Sorrentino,et al.  Potentiation of growth factor activity by exogenous c-myc expression. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[236]  E. Prochownik,et al.  Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation , 1986, Nature.

[237]  E. Dmitrovsky,et al.  Expression of a transfected human c-myconcogene inhibits differentiation of a mouse erythroleukaemia cell line , 1986, Nature.

[238]  A. Kimchi,et al.  Autocrine β-related interferon controls c-myc suppression and growth arrest during hematopoietic cell differentiation , 1986, Cell.

[239]  M. Cole,et al.  Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment , 1986, Nature.

[240]  M. Cole.  The myc oncogene: its role in transformation and differentiation. , 1986, Annual review of genetics.

[241]  F. Alt,et al.  Differential expression of myc family genes during murine development , 1986, Nature.

[242]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[243]  J. Cleveland,et al.  Abrogation of IL-3 and IL-2 dependence by recombinant murine retroviruses expressing v-myc oncogenes , 1985, Nature.

[244]  E. Knight,et al.  Selective reduction of c-myc mRNA in Daudi cells by human beta interferon. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[245]  Robert A. Weinberg,et al.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes , 1983, Nature.

[246]  J. Bishop,et al.  DNA and RNA from Uninfected Vertebrate Cells Contain Nucleotide Sequences Related to the Putative Transforming Gene of Avian Myelocytomatosis Virus , 1979, Journal of virology.

[247]  J. Bishop,et al.  Identification of nucleotide sequences which may encode the oncogenic capacity of avian retrovirus MC29 , 1978, Journal of virology.

[248]  U. Heine,et al.  Strain MC29 avian leukosis virus. Myelocytoma, endothelioma, and renal growths: pathomorphological and ultrastructural aspects. , 1967, Journal of the National Cancer Institute.